HC Wainwright Lifts Earnings Estimates for ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Equities researchers at HC Wainwright upped their Q1 2025 earnings per share estimates for shares of ADC Therapeutics in a research report issued to clients and investors on Monday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their previous estimate of ($0.41). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for ADC Therapeutics' current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics' Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.62) EPS.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.06. The firm had revenue of $19.00 million for the quarter, compared to the consensus estimate of $19.01 million.

Several other analysts have also recently commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Stephens upped their price objective on ADC Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Finally, Guggenheim reduced their target price on ADC Therapeutics from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Monday, March 31st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $7.75.

ADC Therapeutics Trading Down 5.6 %

Shares of ADCT traded down $0.07 on Thursday, reaching $1.11. 98,590 shares of the company's stock were exchanged, compared to its average volume of 454,243. ADC Therapeutics has a 12 month low of $1.05 and a 12 month high of $5.31. The stock has a market capitalization of $109.49 million, a P/E ratio of -0.46 and a beta of 1.55. The business has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $2.18.

Hedge Funds Weigh In On ADC Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ADCT. Kazazian Asset Management LLC bought a new position in ADC Therapeutics during the fourth quarter worth about $26,000. Two Sigma Securities LLC bought a new position in shares of ADC Therapeutics during the 4th quarter valued at about $30,000. Russell Investments Group Ltd. lifted its holdings in shares of ADC Therapeutics by 122.6% during the 4th quarter. Russell Investments Group Ltd. now owns 16,794 shares of the company's stock valued at $33,000 after purchasing an additional 9,248 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of ADC Therapeutics in the 4th quarter valued at approximately $35,000. Finally, Intech Investment Management LLC bought a new stake in ADC Therapeutics during the 3rd quarter worth approximately $41,000. Institutional investors and hedge funds own 41.10% of the company's stock.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.